Cost-effectiveness of cetuximab and panitumumab for chemotherapy-refractory metastatic colorectal cancer

BACKGROUND: Cetuximab and panitumumab are monoclonal antibodies targeting the epidermal growth factor receptor. Both drugs are active against RAS wild type metastatic colorectal cancer after chemotherapy failure, with similar efficacy and toxicity profiles. However, their cost and limited survival b...

Descripción completa

Detalles Bibliográficos
Autores principales: Carvalho, Adriana Camargo, Leal, Frederico, Sasse, Andre Deeke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5389795/
https://www.ncbi.nlm.nih.gov/pubmed/28403233
http://dx.doi.org/10.1371/journal.pone.0175409

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5389795/
https://www.ncbi.nlm.nih.gov/pubmed/28403233
http://dx.doi.org/10.1371/journal.pone.0175409

Ejemplares similares